Epidermal growth factor receptor (EGFR) gene mutation tests were performed in 34.9% (52/149) of patients prior to first‐line treatment, including 38 patients with adenocarcinoma, nine with SCC, and five with other histological types. This evidence concerns the gene EGFR and adenocarcinoma.